The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram

European Journal of Nuclear Medicine

Volumn 24, Issue 10, 1997, Pages 1215-1220

  Stokkel, Marcel ^a,b   Zwinderman, Aeilko ^a   Zwartendijk, Jaap ^a   Pauwels, Ernest ^a   Van Eck Smit, Berthe ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bone scintigraphy; Prognosis; Prostate cancer; Prostate specific antigen; Tumour stage

Indexed keywords

ALKALINE PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CARCINOMA; RETROSPECTIVE STUDY;

AGED; ALKALINE PHOSPHATASE; BONE NEOPLASMS; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030717694     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050144     Document Type: Article

References (34)

1. Soloway MS, Hardeman SW, Hickey D, etal. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
2. Jacobs SC. Spread of metastatic cancer to bone. Urology 1983; 21: 337-344.
3. O'Donoghue JM, Rogers E, Grimes H, etal. A reappraisal of serial isotrope bone scans in prostate cancer. Br J Radiol 1993; 66: 672-676.
4. Freitas JE, Gilvydas R, Ferry JD, Gonzalez JA. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up. J Nucl Med 1991; 32: 1387-1390.
5. Sassine AM, Schulman C. Clinical use of prostate-specific antigen in the staging of patients with prostatic carcinoma. Eur Urol 1993; 23: 348-351.
6. Vijayakumar V, Vijayakumar S, Quadri SF, Blend MJ. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer. Am J Clin Oncol 1994; 17: 432-436.
7. Pantelides ML, Bowman SP, George NJR. Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Br J Urol 1992; 70: 299-303.
8. Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan: significant economic implications. Urol Clin North Am 1993; 20: 705-711.
9. Goad JR, Chang SJ, Ohori M, Scardino PT. PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 1993; 20: 727-736.
10. Petros JA, Andriole GL. Serum PSA after antiandrogen therapy. Urol Clin North Am 1993; 20: 749-756
11. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. Urol Clin North Am 1993; 20: 713-725.
12. Morgan WR, Zincke H, Rainwater LM, Myers RP, Klee GG. Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation). J Urol 1991; 145: 319-323.
13. McGregor B, Tulloch GS, Quinlan MF, Lovegrove F. The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 1978; 50: 178-181.
14. O'Donoghue EPN, Constable AR, Sherwood T, Stevenson JJ, Chisholm GD. Bone scanning and plasma phosphates in carcinoma of the prostate. Br J Urol 1978; 50: 172-177.
15. Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, radiographic and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976; 121: 431-434.
16. Chybowsky FM, Larson Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-318.
17. Oesterlin JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60.
18. Mulders PFA, Fernandez del Moral P, Theeuwes AGM, Oosterhof GON, van Berkel HTH, Debruyne FMJ. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol 1992; 21: 2-5.
19. Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vesselia RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987; 138: 1181-1184.
20. Smith JA, Scaletsky R. Future directions in tumor marker technology for prostate cancer. Urol Clin North Am 1993; 20: 771-777.
21. Hetherington JW, Siddall JK, Cooper EH. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer. Eur Urol 1988; 14: 1-5.
22. Merrick MV, Ding CL, Chisholm GD, Elton RA. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate. Br J Urol 1985; 57: 715-720.
23. Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32: 1713-1717.
24. McCormack RT, Rittenhouse HG, Finlay JA, etal. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995; 45: 729-743.
25. 1-antichymotrypsin. Clin Chem 1991; 37: 1618-1625.
26. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-226.
27. Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostatic-specific antigen, age and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996; 47: 518-524.
28. Partin AW, Yoo J, Ballentine Carter H, etal. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-114.
29. McLaughlin AP, Saltzstein SL, McCullough DL, Gittes RF. Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. J Urol 1976; 115: 89-94.
30. Gervasi LA, Meta J, Easley JD, etal. Prognostic significance of lymph node metastases in prostate cancer. J Urol 1989; 142: 332-336.
31. Schuessler WW, Pharand D, Vancaillie TG. Laparoscopic standard pelvic node dissection for carcinoma of the prostate: is it accurate? J Urol 1993; 150: 898-901.
32. Petros JA, Catalona WJ. Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J Urol 1992; 147: 1574-1575.
33. Danella JF, DeKernion JB, Smith RB, Steckel J. The contemporary incidence of lymph node metastases in prostate cancer: implications of laparoscopic lymph node dissection. J Urol 1993; 149: 1488-1491.
34. Levran Z, Gonzalez JA, Dionko AC, Jafri SZH, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatig cancer Br J Urol 1995; 75: 778-781.